Cantor Fitzgerald Upgrades Cubist Pharmaceuticals (CBST) to Hold

January 24, 2013 8:16 AM EST Send to a Friend
Get Alerts CBST Hot Sheet
Price: $73.60 +0.31%

Rating Summary:
    11 Buy, 10 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 13 | Down: 18 | New: 41
Trade CBST Now!
Join SI Premium – FREE
Cantor Fitzgerald upgraded Cubist Pharmaceuticals (NASDAQ: CBST) from Sell to Hold with a price target of $38.00 (from $37.00).

The firm comments, "We believe the company is facing several "investment" years that are likely to adversely impact the bottom line and the stock should therefore only move upwards on evidence of stronger than expected Cubicin growth and major data catalysts (and no significant events are expected until 2H:13). We anticipate an initial downward reaction in the stock after the earnings call, but we are upgrading to a HOLD since we think that the negative catalyst around 2013 guidance visibility has now played out."

For an analyst ratings summary and ratings history on Cubist Pharmaceuticals click here. For more ratings news on Cubist Pharmaceuticals click here.

Shares of Cubist Pharmaceuticals closed at $42.75 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst EPS View, Analyst PT Change, Upgrades

Related Entities

Cantor Fitzgerald, Earnings

Add Your Comment